Overall, the present data suggest that ERβ may be a novel therapeutic target for the treatment of HAND + drug abuse synaptopathy and early therapeutic intervention with SE may prevent HIV-1 synaptopathy and potentially delay the development of HAND. Here, ESR2 is linked to HIV-associated neurocognitive disorder.